Considerations on the use of oxymorphone in geriatric patients

Expert Opinion on Drug Safety

Volumn 8, Issue 5, 2009, Pages 603-613

  Pergolizzi Jr , Joseph V ^a,b   Raffa, Robert B ^c   Gould, Errol ^d  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Naples Anesthesia and Pain Associates   (United States)

^c TEMPLE UNIVERSITY SCHOOL OF PHARMACY   (United States)

^d ENDO PHARMACEUTICALS INC   (United States)

Author keywords

Analgesia; Geriatric analgesia; Opioids; Oxymorphone; Oxymorphone safety

Indexed keywords

CYTOCHROME P450; DOCUSATE SODIUM; MORPHINE; OPANA; OPANA ER; OPANA INJECTION; OPIATE; OXYCODONE; OXYMORPHONE; PLACEBO; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; AGGRESSION; AGITATION; ANALGESIA; CANCER PAIN; CENTRAL NERVOUS SYSTEM DEPRESSION; CLINICAL TRIAL; COMA; CONFUSION; CONSCIOUSNESS DISORDER; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED RELEASE FORMULATION; CREATINE KINASE BLOOD LEVEL; DECREASED APPETITE; DIARRHEA; DIZZINESS; DOSE RESPONSE; DROWSINESS; DRUG DOSE TITRATION; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; EUPHORIA; FATIGUE; GERIATRIC PATIENT; HEADACHE; HUMAN; HYPOTENSION; ILEUS; LETHARGY; LOW BACK PAIN; NAUSEA; OSTEOARTHRITIS; PAIN; PANCREATITIS; POSTOPERATIVE PAIN; PRURITUS; RESPIRATORY ACIDOSIS; RESPIRATORY DISTRESS; REVIEW; SEDATION; SIDE EFFECT; SOMNOLENCE; ST SEGMENT; SUPRAVENTRICULAR TACHYCARDIA; SWEATING; THORAX PAIN; URINE RETENTION; VOMITING; XEROSTOMIA;

AGED; AGED, 80 AND OVER; ARTHRALGIA; BIOTRANSFORMATION; CLINICAL TRIALS AS TOPIC; CONSTIPATION; DRUG INTERACTIONS; GLUCURONOSYLTRANSFERASE; HUMANS; LIVER; NARCOTICS; NAUSEA; NEOPLASMS; OPIOID-RELATED DISORDERS; OXYMORPHONE; PAIN; PAIN, POSTOPERATIVE; POLYPHARMACY; RECEPTORS, OPIOID, MU; SLEEP STAGES; VOMITING;

EID: 69449085001     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740330903153854     Document Type: Review

References (76)

1. New report finds pain affects millions of Americans. National Center for Health Statistics, CDC. Press release issued November 15, 2006. Available from: http://www.cdc.gov/nchs/ pressroom/06facts/hus06.htm. [Accessed on 28 March 2009]
2. Pain, Chapter 43, Section 6, The merck manual of geriatrics. Available from: http://www.merck.com/mkgr/mmg/sec6/ch43/ ch43a.jsp. [Last accessed on 28 March 2009]
3. Ferrell BR, Ferrell BA, editors, Pain in the elderly. Seattle: IASP Press, 1996
4. Barkin RL, Barkin SJ, Barkin DS. Pharmacotherapeutic management of pain with a focus directed at the geriatric patient. Rhuem Dis Clin North Am 2007;33:1-31
5. Kelley AS, Siegler EL, Reid MC. Pitfalls and recommendations regarding the management of acute pain among hospitalized patients with dementia. Pain Med 2008;9:581-586
6. Pain in the elderly with cancer. WHO pain & palliative care communications Program. Available from: https://whocancerpain. bcg.wise.edu??1=node/206 [Last accessed on 28 March 2009]
7. Gibson SJ, Helme RD. Age-related differences in pain perception and report. Clin Geriatric Med 2001;17:433-456 (Pubitemid 32783029)
8. Gibson SJ, Farrell M. A review of age differences in the neurophysiology of nociception and the perceptual experience of pain. Clin J Pain 2004;20:227-239 (Pubitemid 38802809)
9. Pergolizzi J, Böger RH, Budd K, et al. Opioids and the management of chronic severe pain in the elderly: consensus statement of an international expert panel with focus on the six clinically most often used World Health Organization step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone). Pain Practice 2008;8:287-313 •• Important article on general considerations for opioid therapy in the geriatric population.
10. Closs S. Assessment of pain in older people - the key to effective management. Anaesth Crit Care 2005;16:40-45
11. Gimbel J, Ahdieh H. The efficacy and safety of oral immediate-release oxymorphone for postsurgical pain. Anesth Analg 2004;99:1472-1477 •• Safety and efficacy clinical trial of oxymorphone ER but incidences of various side effects not provided. (Pubitemid 39407301)
12. Beaver WT, Feise GA. A comparison of the analgesic effect of oxymorphone by rectal suppository and intramuscular injection in patients with postoperative pain. J Clin Pharmacol 1977;17:276-291 (Pubitemid 8082192)
13. Aqua K, Gimbel JS, Singla N, et al. Efficacy and tolerability of oxymorphone immediate release for acute postoperative pain after abdominal surgery: a randomized, double-blind, active- and placebo-controlled, parallel-group trial. Clin Ther 2007;29:1000-1012 •• Safety and efficacy clinical trial of oxymorphone ER. (Pubitemid 47198876)
14. Gabrail NY, Dvergsten C, Ahdieh H. Establishing the dosage equivalency of oxymorphone extended release and oxycodone controlled release in patients with cancer pain: a randomized controlled study. Curr Med Res Opin 2004;20:911-916 •• Safety and efficacy clinical trial of oxymorphone ER. (Pubitemid 38821530)
15. Sloan P, Slatkin N, Ahdieh H. Effectiveness and safety of oral extended-release oxymorphone for the treatment of cancer pain: a pilot study. Supp Care Cancer Available from: http://springerlink. metapress.com/media/ D62YFA1MWp6.. butions/F/3/P/7/F3P7M00LCYF79JCY. html/fulltext/html. [Last accessed on 28 March 2009] •• Safety and efficacy clinical trial of oxymorphone ER.
16. Matsumoto AK, Babul N, Ahdieh H. Oxymorphone extended-release tablets relieve moderate to severe pain and improve physical function in osteoarthritis: results of a randomized, double-blind, placebo- and active-controlled phase III trial. Pain Med 2005;5:357-366 •• Safety and efficacy clinical trial of oxymorphone ER. (Pubitemid 41727333)
17. Kivitz A, Ma C, Ahdieh H, Galer BS. A 2-week, multicenter, randomized, double-blind, placebo-controlled, dose-ranging, phase III trial comparing the efficacy of oxymorphone extended release and placebo in adults with pain associated with osteoarthritis of the hip or knee. Clin Ther 2006;28:352-364 •• Safety and efficacy clinical trial of oxymorphone ER. (Pubitemid 43783436)
18. Hale ME, Ahdieh H, Ma TI, Rauck R. Efficacy and safety of OPANA ER (Oxymorphone Extended Release) for relief of moderate to severe chronic low back pain in opioid-experienced patients: a 12-week, randomized, double-blind, placebo-controlled study. J Pain 2007;8:175-184 •• Safety and efficacy clinical trial of oxymorphone ER. (Pubitemid 46186162)
19. Katz N, Rauck R, Ahdieh H, et al. A 12-week, randomized, placebo-controlled trial assessing the safety and efficacy of oxymorphone extended release for opioid naïve patients with chronic low back pain. Curr Med Res Opin 2007;23:117-128 •• Safety and efficacy clinical trial of oxymorphone ER. (Pubitemid 46191677)
20. Rauck R, Ma T, Kerwin R, Ahdieh H. Titration with oxymorphone extended release to achieve long-term pain relief and improve tolerability in opioid-naïve patients with moderate to severe pain. Pain Med 2008;9:777-785 •• Safety and efficacy clinical trial of oxymorphone ER.
21. Chou R, Fanciullo GJ, Fine PG, et al. Opioid treatment guidelines: clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain 2009;10:113-130
22. Christo PJ, Mazioomdoost D. Cancer pain and analgesia. Ann NY Acad Sci 2008;1138:278-298
23. Freye E, Levy JV. Use of opioids in the elderly - pharmacokinetic and pharmacodynamic considerations. AINS 2004;39:527-537 (Pubitemid 39263666)
24. Bernabei R, Gambassi G, Lapane K, et al. Management of pain in elderly patients with cancer. JAMA 1998;279:1877-1882 (Pubitemid 28299283)
25. Chau DL, Walker V, Pai L, Cho LM. Opiates and elderly: use and side effects. Clin Interv Aging 2008;3:273-278 (Pubitemid 352037867)
26. Haijar ER, Hanlon JT, Artz MB. Adverse drug reaction risk factors in older outpatients. Am J Geriatric Pharmacother 2003;1:82-89
27. Johnson JA, Bootman JL. Drug-related morbidity and mortality: a cost-of-illness model. Arch Intern Med 1995;155:1949-1956
28. Classen DC, Pestonik SI, Evans RS, et al. Adverse drug events in hospitalized patients: excess length of stay, extra costs, and attributable mortality. JAMA 1997;277:301-306 (Pubitemid 27045010)
29. Elderly patients prescribed inappropriate medications at 8 percent of doctor visits. National center for health statistics. Available from: http://www.cdc.gov/nchs/ PRESSROOM/04news/elderly.htm. [Last accessed on 28 March 2009]
30. Opana ER 20 mg clinical study. Endo Pharmaceuticals, Chadds Ford, PA. Data on file
31. American Geriatric Society. AGS Clinical Practice Guidelines: pharmacological management of persistent pain in older person. 2009. Available from: http:// www.americangeriatrics.org/education/ executive-summary.shtml. [Accessed 4 June 2009]
32. Beaver WT, Wallenstein SL, Houde RW, Rogers A. comparison of the analgesic effects or oral and intramuscular oxymorphone and of intramuscular oxymorphone and morphine in patients with cancer. J Clin Pharmacol 1977;17:186-198
33. Metzger TG, Paterlini MG, Ferguson DM, et al. Investigation of the selectivity of oxymorphone- and naltrexone-derived ligands via site-directed mutagenesis of opioid receptors: Exploring the "address" recognition locus. J Med Chem 2001;44:857-862
34. Ross FB, Smith MT. The intrinsic antinociceptive effects of oxycodone appear to be kappa-opioid receptor mediated. Pain 1997;73:151-157
35. Adams MP, Ahdieh H. Pharmacokinetics and dose-proportionality of oxymorphone extended release and its metabolites: results of a randomized crossover study. Pharmacotherapy 2004;24:468-476 (Pubitemid 38420533)
36. Lotsch J, Skarke C, Tegeder I, Geisslinger G. Drug interactions with patient-controlled analgesia. Clin Pharmacokinet 2002;41:31-57
37. Liston HL, Markowitz JS, DeVane CL. Drug glucuronidation in clinical psychopharmacology. J Clin Psychophmaracol 2001;21:500-515
38. Nagar S, Raffa RB. Looking beyond the administered drug: metabolites of opioid analgesics. J Fam Pract 2008;57:S1-8 •• This article explores the contribution of metabolites to the overall efficacy and side effects profiles of frequently prescribed analgesics. Knowledge of this information can better inform prescribing practice.
39. Adams M, Pieniaszek HJ, Gammaitoni AR, Ahdieh H. Oxymorphone extended release does not affect CYP2C9 or CYP3A4 metabolic pathways. J Clinc Pharmacol 2005;45:337-345 (Pubitemid 40490430)
40. Cone EJ, Darwin WD, Buchwald WF, Gorodetzky CW. Oxymorphone metabolism and urinary excretion in human, rate, guinea pig, rabbit and dog. Durg metab Dispos 1983;11:446-450
41. Opana package insert. Endo Pharmaceuticals, Chadds Ford, PA
42. Kadiev E, Patel V, Rad P, et al. Role of pharmacogenetics in variable response to drugs: focus on opioids. Expert Opi Drug Metab Toxicol 2008;4:77-91 •• This article examines the effect of genetic variability (polymorphisms) in enzymes, receptors and transporters related to distribution (pharmacokinetics) and pharmacology (pharmcodynamics) of opioids and on the therapeutic efficacy and safety of opioid therapy. (Pubitemid 351234102)
43. Zanger UM, Raimundo S, Eichelbaum M. Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Arch Phmaracol 2004;369:23-37 (Pubitemid 38161221)
44. Gan SH, Ismail R, Wan Adnan WA, Zulmi W. Impact of CYP2D6 genetic polymorphism on tramadol pharmacokinetics and pharmacodynamics. Mol Diagn Ther 2007;11:171-181 (Pubitemid 46983409)
45. Kirchheiner J, Schmidt H, Tzetkov M, et al. Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication. Pharmacogenomics J 2007;7:357-365 (Pubitemid 47202488)
46. Candiotti KA, Yang Z, Rodriguez Y, et al. The impact of CYP2D6 genetic polymorphisms on postoperative morphine consumption. Pain Med 2009. [Epub ahead of print]
47. Nagar S, Remmel RP. Uridine diphosphoglucuronosyltransferase pharmacogenetics and cancer. Oncogene 2006;25:1659-1672
48. Heit HA, Gourlay DL. Urine drug testing in pain medicine. J Pain Symptom Manage 2004;27:260-267
49. Benyamin R, Trescot AM, Datta S. Opioid complications and side effects. Pain Physician 2008;11:S105-20 •• Excellent overview of common side effects of opioid therapy.
50. Nausea and vomiting. Mayo clinic staff. Available from: http://www.mayoclinic. com/health/nausea/DG00019 [Last accessed on 31 March 2009]
51. Porreca F, Ossipov MH. Nausea and vomiting side effects with opioid analgesics during treatment of chronic pain: mechanisms, implications, and management options. Pain Med 2009. [Epub ahead of print] •• This paper reviews the mechanisms by which opioid analgesics produce gastrointestinal side effects such as nausea and vomiting and describes the impact that these side effects have on treatment outcomes in chronic pain patients. Counteractive strategies are also discussed.
52. Nausea, vomiting, constipation, and bowel obstruction in advanced cancer. Available from: http://www.cancer.gov/cancertopics/ pdq/supportivecare/nausea/ HealthProfessional/page8. [Accessed on 16 June 2009]
53. Hagen NA, Foley KM, Cerbone DJ, et al. Chronic nausea and morphine-g-glucuronide. J Pain Symptom Manage 1991;6:125-128
54. Chemoreceptor trigger zone. Available from: http://en.wikipedia.org/wiki/ Chemoreceptor-trigger-zone. [Accessed on 16 June 2009]
55. Thomas J, Karver S, Cooney GA, et al. Methylnatrexone for opioid-induced constipation in advanced illness. N Engl J Med 2008;358:2332-2343 (Pubitemid 351749157)
56. Lembro A, Camilleri M. Chronic constipation. N Engl J Med 2003;349:1360-1368
57. Cameron JC. Constipation related to narcotic therapy: a protocol for nurses and patients. Cancer Nurs 1992;15:372-377
58. Manara L, Bianchi G, Ferretti P, Tavani A. Inhibition of gastrointestinal transit by morphine in rats results primarily from direct drug action on gut opioid investigational sites. J Pharmacol Exp Ther 1986;237:945-949 (Pubitemid 16088118)
59. Swegle JM, Logemann C. Management of common opioid-induced adverse effects. Am Fam Physicians 2006;74:1347-1354 (Pubitemid 44607306)
60. Johanson JF, Sonnenberg A, Koch TR. Clinical epidemiology of chronic constipation. J Clin Gastroenterol 1989;11:525-536
61. Dunlop GM. A study of the relative frequency and importance of gastrointestinal symptoms and weakness in patients with far advanced cancer. Palliat Med 1989;63:37-43
62. Portenoy RK. Constipation in the cancer patient: causes and management. Med Clin North Am 1987;71:303-311
63. Glare P, Lickiss JN. Unrecognized constipation in patients with advanced cancer: a recipe for therapeutic disaster. J Pain Symptom Manage 1992;7:369-371
64. Schug SA, Garrett WR, Gillespie G. Opioid and non-opioid analgesics. Best Pract Res Clin Anaesthesiol 2003;17:91-110
65. Cochen V, Arbus C, Soto ME. Sleep disorders and their impacts on healthy, dependent, and frail older adults. J Nutr Health Aging 2009;13:322-329
66. Mazza M, Della Marca G, De Risio S, et al. Sleep disorders in the elderly. Clin Ther 2004;155:391-394
67. Koren G, Cairns J, Citayat D, et al. Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother. Lancet 2006;368:704 (Pubitemid 44223697)
68. Pickworth WB, Neider GL, Kay DC. Morphinelike arousal by methadone during sleep. Clin Pharmacol Ther 1981;30:796-804
69. Dimsdale JE, Norman D, Dejardin D, Wallace MS. The effect of opioids on sleep architecture. J Clin Sleep Med 2007;3:33-36
70. Ahdieh H, Ma T, Babul N, Lee D. Efficacy of oxymorphone extended release in postsurgical pain: a randomized clinical trial in knee arthroplasty. J Clin Pharmacol 2004;44:767-776 •• Safety and efficacy clinical trial of oxymorphone ER. (Pubitemid 38765938)
71. Peniston JH, Gould E. Oxymorphone extended release for the treatment of chronic low back pain: a retrospective pooled analysis of enriched-enrollment clinical trial data stratified according to age, sex, and prior opioid use. Clin Ther 2009;31:347-359 •• Pooled analysis of oxymorphone safety and efficacy for treatment of lower back pain with stratification by age.
72. Coker E, Papaioannou A, Turpie I, et al. Pain management practices with older adults on acute medical units. Perspectives 2008;32:5-12
73. Bernabei R, Gambassi G, Lapane K, et al. Management of pain in elderly patients with cancer. JAMA 1998;279:1877-1882 (Pubitemid 28299283)
74. Hale ME, Ahdieh H, Ma TI, Rauck R. Efficacy and safety of OPANA ER (Oxymorphone Extended Release) for relief of moderate to severe chronic low back pain in opioid-experienced patients: a 12-week, randomized, double-blind, placebo-controlled study. J Pain 2007;8:175-184 •• Safety and efficacy clinical trial of oxymorphone ER. (Pubitemid 46186162)
75. Kivitz A, Ma C, Ahdieh H, Galer BS. A 2-week, multicenter, randomized, double-blind, placebo-controlled, dose-ranging, phase III trial comparing the efficacy of oxymorphone extended release and placebo in adults with pain associated with osteoarthritis of the hip or knee. Clin Ther 2006;28:352-364 •• Safety and efficacy clinical trial of oxymorphone ER. (Pubitemid 43783436)
76. Matsumoto AK, Babul N, Ahdieh H. Oxymorphone extended-release tablets relieve moderate to severe pain and improve physical function in osteoarthritis: results of a randomized, double-blind, placebo- and active-controlled phase III trial. Pain Med 2005;5:357-366 •• Safety and efficacy clinical trial of oxymorphone ER. (Pubitemid 41727333)